Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DMNFADH)

Drug Name
APR-246 Drug Info
Synonyms Eprenetapopt
Indication
Disease Entry ICD 11 Status REF
Ovarian cancer 2C73 Phase 2 [1]
Bladder cancer 2C94 Phase 1/2 [2]
Gastric adenocarcinoma 2B72 Phase 1/2 [2]
Esophageal cancer 2B70 Phase 1 [1]
Myelodysplastic syndrome 2A37 Phase 1 [1]
Solid tumour/cancer 2A00-2F9Z Preclinical [3]
Cross-matching ID
PubChem CID
52918385
CAS Number
CAS 5291-32-7
TTD Drug ID
DMNFADH

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cellular tumor antigen p53 (TP53) TT7SBF5 P53_HUMAN Stimulator [4]

The Expression Level of Molecule(s) in Normal Tissue of Major ADME-Related Organs

Molecule Molecule Type Gene Name Liver Colon Kidney Small Intestine
Cellular tumor antigen p53 (TP53) DTT TP53 5.257 4.938 5.396 5.626
Molecule Expression Atlas in Normal Tissue of Major ADME-related organs

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Ovarian cancer
ICD Disease Classification 2C73
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Cellular tumor antigen p53 (TP53) DTT TP53 7.01E-01 0.06 0.09
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 ClinicalTrials.gov (NCT04383938) Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies. U.S. National Institutes of Health.
3 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800030246)
4 APR-246/PRIMA-1MET inhibits thioredoxin reductase 1 and converts the enzyme to a dedicated NADPH oxidase. Cell Death Dis. 2013 Oct 24;4:e881.